Suven Pharma Q2 Results: Net profit rises 3% to Rs 82 crore
net profit rose 3% year-on-year (YoY) to Rs 82 crore in Q2FY25 compared to Rs 79.6 crore in the corresponding period of the previous year.
Revenue grew 12% YoY to Rs 258 crore in Q2FY25 driven by 40% growth in CDMO business and consolidation of acquired business.
Suven Pharma acquired 67.5% of Sapala Organics for Rs 229.5 crore in June, boosting nucleic acid therapy and antibody drug conjugate (ADC) technology capabilities.
The EBITDA rose 3.4% YoY to Rs106.3 crore in Q2, while the adjusted EBITDA margins were at 43.3%.
Shares of Suven rose 4.91% to close at Rs 1262.90 on BSE on Wednesday, while the benchmark Sensex declined 1.25% to end 77,690.95 points.
Stock Trading
Stock Investing Made Easy: Beginner's Stock Market Investment Course
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
A2Z of Stock Trading — Online Stock Trading Course
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Market 104: Options Trading: Kickstart Your F&O Adventure
By — Saketh R, Founder- QuickAlpha, Full Time Options Trader
Stock Trading
Macroeconomics Made Easy: Online Certification Course
By — Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant
Stock Trading
Technical Analysis Made Easy: Online Certification Course
By — Souradeep Dey, Equity and Commodity Trader, Trainer
Stock Trading
Commodity Markets Made Easy: Commodity Trading Course
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Technical Analysis for Everyone — Technical Analysis Course
By — Abhijit Paul, Technical
